Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Conestoga Micro Cap Composite 2024 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Conestoga Micro Cap Composite)

Primary Source Intelligence • Q3 2024 Letter Analysis

Conestoga Micro Cap Composite Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Conestoga Micro Cap Composite. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+7.6%

Annualized+10.58%

Digest Analysis

Quick Take

"Slightly trailing the benchmark but demonstrating strong downside protection during volatile periods. Health care led performance with biotech names benefiting from improving funding conditions."

Executive Summary

Conestoga's Micro Cap Composite returned 7.60% net in Q3 2024, slightly underperforming the Russell Microcap Growth Index's 8.57% return amid significant market volatility. The portfolio demonstrated strong downside protection during the July-August selloff, falling only 5.93% versus the benchmark's 14.70% decline. Health Care was the standout sector with Alpha Teknova surging 253% on improving biotech funding conditions and better order activity. Infrastructure spending continued to benefit Construction Partners, which has been a top performer in three of the past four quarters. Technology holdings faced headwinds with Simulations Plus and PROS Holdings declining on execution challenges and industry headwinds. The manager sold PROS due to uncertainty around airline customer spending and added positions in Mama's Creations and Vita Coco to capitalize on consumer staples growth. Environmental services faced regulatory uncertainty following the Supreme Court's Chevron Deference ruling, pressuring Montrose Environmental. The portfolio maintains exposure to secular growth themes including infrastructure spending, biotech innovation, and digital transformation while emphasizing companies with strong competitive moats in niche markets.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The manager demonstrates moderate-high conviction through concentrated positions (top 10 holdings represent 41.86% of assets), specific company analysis with detailed rationales for buys and sells, and willingness to maintain sector overweights despite underperformance. Clear thesis articulation for individual holdings supports this score.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager acknowledges market volatility with VIX reaching 65.7 but expresses cautious optimism about improving conditions in biotech funding and continued infrastructure spending. The tone is measured rather than strongly bullish or bearish.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

The portfolio maintains sector overweights and continues adding new positions, but the manager is selective in deployment, selling underperforming names like PROS while adding defensive consumer staples positions. Risk appetite is moderate but cautious.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

Limited net deployment activity with only two new positions added (MAMA and COCO) while selling one position (PRO). More trimming and adding to existing positions than major new capital deployment. Represents selective, measured activity rather than aggressive deployment.

Forward Guidance

10%

CautiousExpansionary

Cautious (10%)

The manager indicates continued focus on secular themes and expects volatility to persist. No aggressive deployment signals, with emphasis on maintaining current positioning and selective additions based on fundamentals.

Language Signal

20%

BearishBullish

Bearish (20%)

Language includes positive terms like 'improving biotech funding environment' and 'strong competitive advantages' but is balanced with risk language around 'uncertainty,' 'headwinds,' and 'volatility.' Slightly more constructive than negative overall.

Perceived Risk

72%

Low RiskElevated

Elevated Risk (72%)

Manager explicitly discusses elevated volatility with VIX at highest levels since March 2020, regulatory uncertainty from Chevron Deference ruling, and continued concerns about biotech industry spending patterns. Multiple specific risk factors are identified and discussed in detail.

Opportunity Density

45%

ScarceAbundant

Selective (45%)

Manager sees selective opportunities in specific areas like improving biotech funding and infrastructure spending, but overall tone suggests a more challenging environment requiring careful stock selection. Opportunities exist but are not abundant across the market.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

The manager discusses secular growth themes, long-term competitive advantages, and multi-year trends like infrastructure spending programs. References to companies building platforms and market share expansion suggest a patient, multi-year investment approach typical of growth investing.